High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Lehmann, Annika ^a   Denkert, Carsten ^a   Budczies, Jan ^a   Buckendahl, Ann Christin ^a   Darb Esfahani, Silvia ^a   Noske, Aurelia ^b   Müller, Berit M ^a   Bahra, Marcus ^a   Neuhaus, Peter ^a   Dietel, Manfred ^a   Kristiansen, Glen ^b   Weichert, Wilko ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; ENZYME INHIBITOR; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION; ADENOCARCINOMA; CELL NUCLEUS; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL NUCLEUS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TRANSCRIPTION FACTOR RELA;

EID: 71049115609     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-395     Document Type: Article

References (33)

1. Richards EJ, Elgin SCR. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 2002, 108:489-500. 10.1016/S0092-8674(02)00644-X, 11909520.
2. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202. 10.1038/35106079, 11902574.
3. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552. 10.1038/sj.onc.1210620, 17694093.
4. de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370:737-749. 1223209, 12429021, 10.1042/BJ20021321.
5. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001, 58:728-736. 10.1007/PL00000896, 11437234.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428. 10.1038/nrg962, 12042769.
7. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003, 46:5097-5116. 10.1021/jm0303094, 14613312.
8. Yoshida M, Matsuyama A, Komatsu Y, Nishino N. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 2003, 10:2351-2358. 10.2174/0929867033456602, 14529478.
9. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007, 25:84-90. 10.1038/nbt1272, 17211407.
10. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51. 10.1038/nrc1779, 16397526.
11. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784. 10.1038/nrd2133, 16955068.
12. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007, 16:1111-1120. 10.1517/13543784.16.7.1111, 17594194.
13. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
14. Wadler S. Molecular targeting in pancreatic cancer. Rev Recent Clin Trials 2007, 2:69-75. 10.2174/157488707779318152, 18473990.
15. Arlt A, Gehrz A, Müerköster S, Vorndamm J, Kruse M, Fölsch UR, Schäfer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003, 22:3243-3251. 10.1038/sj.onc.1206390, 12761494.
16. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse M, Sebens T, Klöppel G, Kalthoff H, Fölsch UR, Schäfer H. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004, 64:1331-1337. 10.1158/0008-5472.CAN-03-1860, 14973050.
17. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260. 10.1146/annurev.immunol.16.1.225, 9597130.
18. Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann H, Niesporek S, Jacob J, Dietel M, Scheidereit C, Kristiansen G. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007, 97:523-530. 2360349, 17622249, 10.1038/sj.bjc.6603878.
19. Karin M, Cao Y, Greten FR, Li Z. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310. 10.1038/nrc780, 12001991.
20. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 2005, 3:100-109. 10.1158/1541-7786.MCR-04-0070, 15755876.
21. Lüttges J, Schemm S, Vogel I, Hedderich J, Kremer B, Klöppel G. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol 2000, 191:154-161. 10.1002/(SICI)1096-9896(200006)191:2<154::AID-PATH603>3.0.CO;2-C, 10861575.
22. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MPA, Pross M, Dietel M, Denkert C, Röcken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008, 9:139-148. 10.1016/S1470-2045(08)70004-4, 18207460.
23. Wilson AJ, Byun D, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006, 281:13548-13558. 10.1074/jbc.M510023200, 16533812.
24. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005, 12:395-404. 10.1038/sj.cdd.4401567, 15665816.
25. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008, 98:604-610. 2243142, 18212746, 10.1038/sj.bjc.6604199.
26. Weichert W, Röske A, Niesporek S, Noske A, Buckendahl A, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008, 14:1669-1677. 10.1158/1078-0432.CCR-07-0990, 18347167.
27. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, Morine Y, Shimada M. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008, 36:e1-9. 10.1097/MPA.0b013e31815f2c2a, 18362831.
28. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006, 281:5612-5622. 10.1074/jbc.M507213200, 16377638.
29. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006, 66:5409-5418. 10.1158/0008-5472.CAN-05-4225, 16707469.
30. Chen LF, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001, 293:1653-1557. 10.1126/science.1062374, 11533489.
31. Göttlicher M, Minucci S, Zhu P, Krämer O, Schimpf A, Giavara S, Sleeman J, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20:6969-6978. 125788, 11742974, 10.1093/emboj/20.24.6969.
32. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 2004, 239:763-9. discussion 769-71., 1360122, 15166955, 10.1097/01.sla.0000128681.76786.07.
33. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao M, Evans DB, Abbruzzese JL, McDonnell TJ, Chiao PJ. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002, 21:6510-6519. 10.1038/sj.onc.1205848, 12226754.